ISAAC KUFFOUR: Open Payments
NPI 1568233229 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$551 in 22 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $18 · 2025 $551
Food & beverage: $551
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 8 | $218 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $89 |
| E.R. Squibb & Sons, L.L.C. | 3 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Neurocrine BioSciences, Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 1 | $38 |
| Alkermes, Inc. | 1 | $21 |
Products named: INVEGA SUSTENNA, CAPLYTA, COBENFY, ABILIFY ASIMTUFII, INGREZZA, UZEDY, ARISTADA.
Industry payments across CA — which companies pay providers there.
